Aurobindo Pharma

1,191.30
+35.20
(3.04%)
ann
There are new updates from the company1 day ago
Viewcross
right
Market Cap
67,146.50 Cr
EPS
59.81
PE Ratio
20.01
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,592.00
52 Week Low
1,010.00
PB Ratio
2.14
Debt to Equity
0.21
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from26 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.77 %
+80.77 %
Hold
Hold+3.85 %
+3.85 %
Sell
Sell+15.38 %
+15.38 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,676.30
#1 4,03,016.30
35.07
#1 52,041.20
12.06
#1 10,980
-18.99
48.33
6,906.50
1,82,536.20
83.65
9,360.00
0.89
2,117
23.05
68.54
1,513.30
1,21,858.90
23.76
28,409.50
7.12
5,291
30.28
54.26
3,368.00
1,12,841.10
59.12
11,317.00
11.59
2,054
10.91
62.08
1,307.40
1,07,768.20
#1 19.63
33,741.20
12.36
5,725
21.14
54.13
1,001.00
1,00,563.00
21.57
22,573.80
13.82
3,977
-0.19
69.99
2,439.50
97,474.10
50.68
12,207.40
19.57
1,925
-10.91
59.65
1,980.90
89,274.80
27.51
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,735.00
75,265.00
52.20
6,409.15
10.80
1,417
27.83
64.97
1,191.30
#10 67,146.50
#2 20.01
#3 31,378.10
#3 17.55
#5 3,366
#8 -0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
17.55 %
Net Income Growth
64.39 %
Cash Flow Change
2.00 %
ROE
47.91 %
ROCE
46.65 %
EBITDA Margin (Avg.)
35.82 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,397
9,374
10,532
11,024
14,493
19,076
Current Assets
8,299
10,294
9,206
12,178
15,332
16,413
19,824
18,123
21,460
23,772
27,163
Capital Work in Progress
420
848
1,458
1,583
1,669
1,986
3,062
3,747
5,390
3,869
3,266
Investments
20
123
246
312
360
555
591
997
543
372
10,544
Other Assets
8,770
10,769
9,712
12,686
15,951
16,991
20,828
18,645
22,934
26,338
0
Total Liabilities
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Current Liabilities
6,136
7,840
6,606
8,666
12,021
11,385
10,665
8,156
11,494
12,199
14,682
Non Current Liabilities
1,596
790
270
753
541
718
1,260
1,192
1,544
3,022
2,456
Total Equity
5,182
7,290
9,374
11,682
13,892
16,825
21,929
24,574
26,852
29,851
32,653
Reserve & Surplus
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
Share Capital
29
59
59
59
59
59
59
59
59
59
58

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
Investing Activities
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
Operating Activities
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,017
2,387
2,435
Financing Activities
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
51.94 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.80 %
51.82 %
51.82 %
51.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
18.02 %
16.73 %
16.59 %
16.29 %
15.33 %
DIIs
10.99 %
12.72 %
13.82 %
15.11 %
15.83 %
15.58 %
16.23 %
14.89 %
15.08 %
15.73 %
17.94 %
20.23 %
23.28 %
24.77 %
25.13 %
25.20 %
26.23 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.71 %
8.54 %
9.60 %
8.99 %
8.37 %
8.80 %
8.65 %
9.42 %
8.54 %
7.01 %
6.15 %
5.64 %
5.52 %
5.47 %
5.33 %
5.52 %
5.47 %
Others
28.36 %
26.91 %
24.74 %
24.07 %
23.97 %
23.79 %
23.29 %
23.85 %
24.54 %
25.42 %
24.07 %
22.29 %
1.36 %
1.23 %
1.13 %
1.17 %
1.15 %
No of Share Holders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962
2,69,323

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 2.5 2.5 3 4 9 7.5 4.5 0.00
Dividend Yield (%) 0.00 0.57 0.32 0.61 0.34 0.6 1.77 0.69 0.39 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 1,201.85 1,179.35
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,178.35 1,191.50
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 1,400.70 1,327.55
29 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Aug 2024 1,399.45 1,562.15
20 Feb 2024 DIVIDEND Dividend
₹ 1.50 /share
20 Feb 2024 1,002.00 1,052.40
20 Nov 2023 DIVIDEND Dividend
₹ 3.00 /share
20 Nov 2023 950.75 1,021.15
17 Feb 2023 DIVIDEND Dividend
₹ 3.00 /share
17 Feb 2023 440.70 473.20
07 Jun 2022 DIVIDEND Dividend
₹ 4.50 /share
06 Jun 2022 528.60 516.35
21 Feb 2022 DIVIDEND Dividend
₹ 1.50 /share
18 Feb 2022 656.05 639.05
18 Nov 2021 DIVIDEND Dividend
₹ 1.50 /share
17 Nov 2021 672.40 639.35
30 Aug 2021 DIVIDEND Dividend
₹ 1.50 /share
27 Aug 2021 825.70 716.05
23 Feb 2021 DIVIDEND Dividend
₹ 1.50 /share
22 Feb 2021 967.85 853.60
21 Jul 2015 BONUS Bonus
1:1
20 Jul 2015 0.00 0.00

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20181 day ago
Announcement under Regulation 30 (LODR)-Restructuring2 days ago
Curateq Biologics Receives Marketing Approval For Trastuzumab Biosimilar Dazublysâ„¢ From European Commission2 days ago
Announcement under Regulation 30 (LODR)-Updates on Acquisition4 days ago
Restart Of Penicillin-G Production At Our Kakinada Facility Post Receipt Of Consent To Operate From Andhra Pradesh Pollution Control Board5 days ago
Closure of Trading Window8 days ago
Curateq Biologics S.R.O A Wholly Owned Step-Down Subsidiary Of The Company Receives Approval For Biosimilar Dyrupeg From UKS MHRA10 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Order Received From Customs Excise And Service Tax Appellate Tribunal (CESTAT) ChennaiJun 06, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
Update On Safety Incident Of April 27 2025 At Lyfius Pharma Private Limited (A Wholly Owned Stepdown Subsidiary Of The Company)May 26, 2025
Appointment Of Secretarial AuditorsMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 26 2025May 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Board Meeting Intimation for Intimation Of Board Meeting.May 16, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 30, 2025
Intimation Regarding A Safety Incident On April 27 2025 At Lyfius Pharma Private Limited (A Wholly Owned Stepdown Subsidiary Of The Company).Apr 28, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 12, 2025
Completion Of US FDA Inspection At Raleigh Plant North Carolina Owned By Aurolife Pharma LLC A Wholly Owned Step-Down Subsidiary Of The CompanyApr 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 09, 2025
Curateq Biologics Received Marketing Authorization For Dyrupegâ„¢ A Pegylated Filgrastim BiosimilarApr 05, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 31, 2025
Cautionary Email Received From The Stock Exchanges Regarding Delay In Intimation Of Schedule Of Investors MeetMar 28, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Closure of Trading WindowMar 25, 2025
Allotment Of Compulsory Convertible Preference Shares To Dr. Satakarni Makkapati By Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company.Mar 21, 2025
Classification Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company - Reg.Mar 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Termination Of License Agreement With Hilleman Laboratories Singapore Pte Limited By Auro Vaccines Private LimitedMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025

Technical Indicators

RSI(14)
Neutral
55.14
ATR(14)
Less Volatile
27.86
STOCH(9,6)
Neutral
71.11
STOCH RSI(14)
Overbought
97.77
MACD(12,26)
Bullish
6.51
ADX(14)
Weak Trend
14.96
UO(9)
Bearish
50.67
ROC(12)
Uptrend And Accelerating
4.18
WillR(14)
Overbought
-12.91

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Hybrid Equity Fund Direct Plan-Growth
0.54%
-740509
-0.43%
-0.40%
Kotak Arbitrage Fund Direct-Growth
0.41%
642950
0.07%
0.05%
Mirae Asset Midcap Fund Direct - Growth
1.95%
583359
0.20%
0.25%
Nippon India Vision Large & Mid Cap Direct-Growth
0.85%
-400000
-0.94%
-0.92%
ICICI Prudential Business Cycle Fund Direct - Growth
0.38%
-369388
-0.41%
-0.40%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
1.13%
340000
0.05%
0.07%
ICICI Prudential India Opportunities Fund Direct - Growth
1.48%
322686
-0.02%
-0.02%
ICICI Prudential Large Cap Fund Direct-Growth
0.51%
300000
0.00%
0.09%
ICICI Prudential Innovation Fund Direct - Growth
1.93%
190300
0.15%
0.59%
Bandhan Arbitrage Fund Direct-Growth
0.97%
185350
0.15%
0.21%
ICICI Prudential Equity Arbitrage Direct-Growth
0.50%
184250
0.02%
-0.03%
Invesco India Arbitrage Fund Direct-Growth
0.21%
176550
0.07%
0.02%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.64%
171600
0.02%
0.40%
HDFC Balanced Advantage Fund Direct-Growth
0.31%
-169400
-0.05%
-0.04%
Tata Arbitrage Fund Direct - Growth
0.73%
126500
-0.02%
-0.11%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.46%
118800
-0.01%
-0.05%
SBI Arbitrage Opportunities Fund Direct-Growth
0.49%
83600
-0.03%
-0.06%
Edelweiss Arbitrage Fund Direct-Growth
0.31%
77550
0.03%
-0.01%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
3.82%
-70000
-1.30%
-1.04%
HDFC Retirement Savings Fund Equity Plan Direct-Growth
0.53%
-60000
-0.18%
-0.26%
Bank of India Multi Cap Fund Direct-Growth
0.68%
50809
0.68%
0.68%
ICICI Prudential Exports and Services Fund Direct-Growth
0.00%
-43423
-0.39%
-0.82%
Baroda BNP Paribas Arbitrage Fund Direct - Growth
0.41%
42900
0.41%
0.41%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-36562
-1.40%
0.00%
Bank of India Manufacturing & Infrastructure Fund Direct-Growth
0.67%
33597
0.67%
0.67%

About Aurobindo Pharma

Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has 9 R&D facilities. APL has filed numerous Drug Master Files and Abbreviated New Drug Applications in various countries. The company has expanded through acquisitions and joint ventures in multiple countries, including the UK, Italy, and Portugal. APL has also entered the biosimilars and vaccines markets. The company serves over 150 countries and is among the top 5 manufacturers of semi-synthetic penicillins globally.
Chairperson NameM R Kumar